Search Results
Results 201 - 250 of 2722
< 1 2 3 4 5 6 7 8 9 10 >
Horjeti Blendi - - 2011
We presented a patient suffering an acute anterior myocardial infarction, immediately after an insect sting. Coronary angiogram showed thrombosis of a drug-eluting stent, implanted 15months ago in proximal LAD. Primary PCI was performed immediately. This is an ambiguous case of late DES thrombosis or Kounis syndrome. The association between them ...
Ruperto Cettina - - 2010
Studies of percutaneous coronary intervention (PCI) with drug-eluting stents in high-risk scenarios are often limited by short follow up and use definitions of "off-label" PCI which do not entirely mirror insert packages recommendations. We analyzed the incidence of cardiovascular events in 1050 consecutive patients undergoing off-label PCI with sirolimus- (n=581) ...
Park Duk-Woo - - 2009
BACKGROUND: Although C-reactive protein (CRP) has been proposed as a useful biomarker for predicting atherothrombosis, the association between CRP and stent thrombosis after drug-eluting stent implantation has not been defined. METHODS AND RESULTS: We prospectively evaluated 2691 patients treated with drug-eluting stents who had a baseline CRP measurement. The primary ...
Hoppmann Petra - - 2009
After novel findings from genomewide association studies that sequence variation on chromosome 9p21.3 is a genetic factor for coronary heart disease, we investigated whether this locus influenced the clinical and angiographic outcomes after implantation of drug-eluting stents in coronary arteries. Recently, genomewide association studies have identified a locus on chromosome ...
Atary Jael Z - - 2009
AIMS: To evaluate effects of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) at stent edges in patients with acute myocardial infarction (AMI). METHODS AND RESULTS: Clinical, angiographic, intravascular ultrasound (lVUS) and virtual histology (VH)-IVUS results were obtained and analysed in 20 SES and 20 BMS AMI patients at the ...
Chen Shih-fan - - 2009
The development of drug-eluting stents (DES) is one of the critical milestones in the advances of interventional cardiology. However, clinical stent thrombosis still poses a serious potential complication. In acute ST-segment elevation myocardial infarction (STEMI), acute total vessel occlusion has a larger thrombus burden, and the use of DES in ...
Steadman Christopher D - - 2009
Percutaneous techniques are being increasingly used in adult congenital heart disease but there is limited experience in the treatment of native nonvalvar right ventricular outflow tract obstruction. We describe two cases of percutaneous stenting of the subpulmonary region where surgery was not an option.
Arat-Ozkan Alev - - 2009
We report a case with exaggerated stent protrusion from the right coronary ostium into the aorta leading to recurrent inferoposterior and right ventricular myocardial infarctions due to stent thrombosis, which were treated successfully with fibrinolysis. The stent was removed via transverse aortotomy and two bypass grafts were performed. Stents protruding ...
Maehara Akiko - - 2009
BACKGROUND: Vascular responses to drug-eluting stents in ST-segment elevation myocardial infarction are unknown. In the prospective, multicenter Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with ST-segment elevation myocardial infarction within 12 hours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxel-eluting stents (PES) ...
Cuisset Thomas - - 2009
A low response to clopidogrel has been associated with an increased risk of stent thrombosis. However, the definition of a nonresponse to clopidogrel remains controversial, and different tests have been used to assess the clopidogrel response. The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced ...
Jones W S - - 2009
Coronary heart disease is a leading cause of death around the world. The treatment of acute myocardial infarction has evolved with the advent of novel thrombolytic agents, anticoagulants, antiplatelets, and innovative percutaneous techniques. The development of drug-eluting stents has dramatically lowered the risk of in-stent restenosis compared to bare metal ...
Ehdaie A - - 2009
Drug-eluting stents (DES) have been approved by the Food and Drug Administration for percutaneous coronary intervention (PCI) in the treatment of stable coronary disease but not in the treatment of acute myocardial infarction. In the past, treatment of acute myocardial infarction was mainly done via thrombolysis and balloon angioplasty. Although ...
Valgimigli Marco - - 2009
The controversial choice between bare metal stents and drug-eluting stents (DES) in primary percutaneous coronary intervention (PCI) seems to be driven by a growing body of evidence. Although evidence supporting the use of DES in the setting of ST-segment elevation myocardial infarction (STEMI) has been demonstrated, including a lower target ...
Colombo Francesco - - 2009
BACKGROUND: After the first exciting results on drug-eluting stents (DES), many concerns have been raised on their potential risk for late stent thrombosis. Whereas DES appear beneficial at early and mid-term for coronary bifurcation lesions, no data are available on their long-term safety in this setting in comparison to bare ...
Capodanno Davide - - 2009
BACKGROUND: The potential for the CATANIA (CAT) stent to be an alternative to both bare-metal stents (BMS) and drug-eluting stents (DES) has been recently demonstrated in the Assessment of The LAtest Non-Thrombogenic Angioplasty stent (ATLANTA) first-in-human study. The aim of the present study was to compare short-term outcomes of patients ...
Jokhi Percy P - - 2009
Iatrogenic coronary perforation complicates 0.1-0.8% of percutaneous coronary interventional (PCI) procedures. The incidence is higher if atheroablative therapy is used. When coronary perforation occurs, it may rapidly result in cardiac tamponade, myocardial infarction or death, hence prompt treatment is required. PTFE-covered stents have been used to seal coronary perforations, but ...
Klomp Margo - - 2009
BACKGROUND: In the treatment of coronary artery disease, a "pro-healing" approach for prevention of in-stent restenosis and late stent thrombosis is intuitively favored over the use of cytotoxic or cytostatic drugs released from a drug-eluting stent (DES). Promoting accelerated endothelial coverage of the stent surface, the endothelial progenitor cell (EPC) ...
Kim Sung Soo - - 2009
Drug-eluting stents (DES) are considered the treatment of choice for most patients with obstructive coronary artery disease when percutaneous intervention (PCI) is feasible. However, stent thrombosis seems to occur more frequently with DES and occasionally is associated with resistance to anti-platelet drugs. We have experienced a case of recurrent stent ...
Silber Sigmund - - 2009
BACKGROUND: The TAXUS II trial was designed to evaluate the safety and efficacy of the commercialized slow-release (SR) and an investigation-only moderate-release (MR) polymer-based TAXUS paclitaxel-eluting stent compared with a bare-metal stent for the treatment of de novo coronary lesions. METHODS AND RESULTS: This prospective, randomized, double-blind, controlled trial enrolled ...
Nienaber Christoph A - - 2009
The prospective multicenter German Drug-Eluting Stent (DES.DE) registry is an observational study to analyze and evaluate the therapeutic principle of the differential drug-eluting stents (sirolimus- and paclitaxel-eluting stents) and bare metal stents under real world conditions in the context of the German healthcare system. The baseline clinical and angiographic characteristics ...
Kim Hyun-Sook - - 2011
Meta-analysis of randomized trials showed superior efficacy and similar safety of drug-eluting stent over bare-metal stent in acute ST-elevation myocardial infarction (STEMI) patients. However, long-term relative outcomes of sirolimus- (SES) vs. paclitaxel-eluting stent (PES) have not been fully evaluated in randomized studies. This study compared long-term safety and efficacy of ...
Lee Cheol Whan - - 2009
Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This ...
Katritsis Demosthenes G - - 2009
BACKGROUND: Several trials have addressed whether bifurcation lesions require stenting of both the main vessel and side branch, but uncertainty remains on the benefits of such double versus single stenting of the main vessel only. METHODS AND RESULTS: We have conducted a meta-analysis of randomized trials including patients with coronary ...
Lagerqvist Bo - - 2009
BACKGROUND: The objective was to evaluate the role of risk factors and stent type for stent thrombosis (ST) using a large real world registry. METHODS AND RESULTS: We evaluated all consecutive coronary stent implantations in Sweden from May 1, 2005, to June 30, 2007. All cases of ST, documented in ...
Ergelen Mehmet - - 2010
BACKGROUND: One of the major concerns remaining in the treatment with stenting of patients with acute myocardial infarction (AMI) is the occurrence of stent thrombosis (ST). The aim of the current study is to investigate the incidence, predictors, and long-term outcomes of early ST after primary coronary stenting for AMI ...
Lichtenwalter Christopher - - 2009
We sought to compare the clinical presentation and angiographic patterns of saphenous vein graft (SVG) failure after stenting with a paclitaxel-eluting stent (PES) versus a similar bare-metal stent (BMS). The mode of SVG failure after stenting has been poorly characterized. The SOS (Stenting Of Saphenous Vein Grafts) trial enrolled 80 ...
Karakurt Ozlem - - 2009
A 40-year-old male patient was admitted to the hospital with acute chest pain. A sirolimus-eluting stent (SES) had been deployed to the circumflex artery (Cx) 3 years before. Now, inferior ST-segment elevations were observed and coronary angiography revealed stent thrombosis with distal TIMI 3 grade flow in the Cx. Tirofiban ...
Byrne Robert A - - 2009
Although biodegradable polymer drug-eluting stent (DES) platforms have potential to enhance long-term clinical outcomes, data concerning their efficacy are limited to date. We previously demonstrated angiographic antirestenotic efficacy with a microporous, biodegradable polymer DES. In the current study, we hypothesized that at 12 months, its clinical safety and efficacy would ...
Nikolsky Eugenia - - 2009
BACKGROUND: In the 300-patient SPIRIT II and 1002-patient SPIRIT III randomized trials, the everolimus-eluting stent (EES) compared to the paclitaxel-eluting stent (PES) resulted in reduced angiographic late loss (a primary end point in both trials), noninferior rates of 9-month target vessel failure (a primary end point in SPIRIT III), and ...
Lee Jong-Young - - 2009
OBJECTIVES: The aim of this study was to evaluate long-term clinical outcomes after implantation of sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) among patients with unprotected left main coronary artery (LMCA) disease. BACKGROUND: There have been few comparisons of long-term outcomes among currently available drug-eluting stents (DES) for the treatment ...
Nef Holger M - - 2009
AIMS: Restenosis in bare-metal stents is in part related to stent design and material. Optimized strut design of cobalt-chrome (CoCr) stents may yield nearly comparable results to drug-eluting stents (DES) in selected lesions. The prospective multicenter DaVinci registry investigates the clinical outcome of a CoCr coronary stent (MULTI-LINK VISION), particularly ...
Buszman Pawel E - - 2009
OBJECTIVES: The aim of the study was to evaluate early and late outcomes after percutaneous coronary intervention (PCI) of unprotected left main coronary artery disease (ULMCA) and to compare bare-metal stent (BMS) and drug-eluting stent (DES) subgroups. BACKGROUND: PCI is an increasingly utilized method of revascularization in patients with ULMCA. ...
Gil Robert J - - 2009
Background:The two main problems unresolved in coronary bifurcation stenting are periprocedural side branch compromise and higher restenosis at long term. The purpose of this study is to reveal the link between periprocedural side branch compromise and long-term results after main vessel stenting only in coronary bifurcations. Methods:Eighty-four patients formed the ...
Heestermans A A C M - - 2009
BACKGROUND: No randomized comparisons are yet available evaluating the effect of pre-hospital high dose tirofiban on the incidence of early stent thrombosis after primary percutaneous coronary intervention (PCI). OBJECTIVES: The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) ...
Khattab Ahmed A - - 2009
BACKGROUND: Studies continue to identify percutaneous coronary intervention procedural volume both at the institutional level and at the operator level as being strongly correlated with outcome. High-volume centers have been defined as those that perform >400 percutaneous coronary intervention procedures per year. The relationship between drug-eluting stent procedural volume and ...
Novack Victor - - 2009
The aim of this study was to compare outcomes among unselected patients undergoing percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting stents (PES). Although the benefits of both SES and PES are well-established, studies comparing these stents directly have yielded conflicting results. We used data from the EVENT ...
Leibundgut Gregor - - 2009
BACKGROUND: The long-term safety of drug-eluting stents (DES) for the treatment of ST-segment elevation myocardial infarction (STEMI) is unclear and may differ from that in stable angina (stable) patients as noted in autopsy studies. METHODS: To assess this problem, 210 consecutive STEMI and 323 stable patients, randomized 2:1 to DES ...
Perez Gilberto - - 2009
BACKGROUND: Semisynthetic coating of the Camouflage bare-metal stent (BMS) (Eucatech AG, Rheinfelden, Germany) mimics luminal endothelial cell glycocalix, potentially preventing the activation of the coagulation system. Purpose. We sought to determine in a clinical registry the acute and long-term clinical and angiographic outcomes of this BMS design in patients with ...
Piscione Federico - - 2009
OBJECTIVES: To evaluate outcome of patients undergoing sirolimus-eluting stent (SES) as compared to bare-metal stent (BMS) implantation during primary angioplasty for ST-segment elevation myocardial infarction (STEMI). BACKGROUND: The role of SES in primary percutaneous coronary intervention setting is still debated. METHODS: We searched Medline, EMBASE, CENTRAL, scientific session abstracts, and ...
Milicic Davor - - 2009
A 56-year-old male was admitted for elective percutaneous coronary intervention. Four days later he developed subacute stent thrombosis in the proximal stent in his right coronary artery. Using the Multiplate(R) ASPI and ADP test, we detected combined aspirin and clopidogrel resistance. The doses of aspirin and clopidogrel were increased to ...
Zhang F - - 2009
BACKGROUND: Coronary bifurcation lesions remain a challenge for interventional cardiologists and the optimal stenting strategy has not been established in the current drug-eluting stent (DES) era. This study compared two strategies for DES treatment of coronary bifurcation lesions: a simple stenting approach (stenting only the main vessel (MV) and provisional ...
Kim Young-Hak - - 2009
BACKGROUND: Limited information is available on long-term outcomes for patients with unprotected left main coronary artery disease who received drug-eluting stents (DES). METHODS AND RESULTS: In the multicenter registry evaluating outcomes among patients with unprotected left main coronary artery stenosis undergoing stenting with either bare metal stents (BMS) or DES, ...
Cook Stéphane - - 2009
BACKGROUND: Intravascular ultrasound of drug-eluting stent (DES) thrombosis (ST) reveals a high incidence of incomplete stent apposition (ISA) and vessel remodeling. Autopsy specimens of DES ST show delayed healing and hypersensitivity reactions. The present study sought to correlate histopathology of thrombus aspirates with intravascular ultrasound findings in patients with very ...
Onuma Yoshinobu - - 2009
OBJECTIVES: The purpose of this study was to investigate the impact of everolimus-eluting stents (EES) in comparison with bare-metal stents (BMS), sirolimus-eluting stents (SES), and paclitaxel-eluting stents (PES) on the 6-month clinical outcomes in an all-comer population. BACKGROUND: EES have been shown to be effective in the context of randomized ...
Sukhija Rishi - - 2009
BACKGROUND: Although insertion of multiple stents into a single coronary vessel during single-vessel percutaneous coronary intervention (PCI) is common, there are no data on long-term occurrence of major adverse cardiac events (MACE) in patients treated with multiple stents versus a single stent. METHODS: The incidence of MACE (death, myocardial infarction, ...
Delhaye Cédric - - 2009
BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) elevation is associated with poor clinical outcome in patients with coronary artery disease (CAD). However, the prognostic value of preprocedural hs-CRP elevation before coronary stent implantation remains debated especially regarding restenosis and target vessel revascularization (TVR). Furthermore, whether hs-CRP elevation may predict stent thrombosis (ST) ...
Khalilov Sh D - - 2009
The target of research is to compare the changes of systolic and diastolic functions of the left ventricle in patients with at least one month infarction after infarct-dependent artery recanalization through elective stenting. The group of 60 patients was selected, 47 men and 13 women, who underwent hospitalization in Central ...
Shammas Nicolas W - - 2009
BACKGROUND: The paclitaxel drug-eluting stent (Taxus, Boston Scientific) is FDA approved for treatment of coronary artery disease in simple, noncomplex coronary lesions. In this registry, we sought to investigate the procedural success and long-term outcomes of patients receiving the Taxus stent in the setting of acute ST-elevation myocardial infarction (STEMI) ...
Yang Hyoung-Mo - - 2009
OBJECTIVES: We aimed to evaluate long-term outcomes of a modified mini-crush technique for treating bifurcation lesions. BACKGROUND: Coronary bifurcation lesions continue to show a relatively high restenosis rate despite the use of a drug-eluting stent (DES). METHODS: We enrolled 52 consecutive patients treated with sirolimus-eluting stent implantation using the modified ...
Shim Jae Hoon - - 2009
The progress in anti-platelet therapy and percutaneous coronary intervention led to reconfigure indications of hybrid re-vascularisation. However, there are still some controversies over indication, timing and patient management during the procedure. The case discussed here is a patient who was diagnosed with myocardial infarction and treated with hybrid re-vascularisation. The ...
< 1 2 3 4 5 6 7 8 9 10 >